TD2 Oncology

Flow Cytometry Friday: Profiling a Killer at the Scene of the Crime NK cells are the immune system’s rapid-response team—swiftly recognizing and eliminating infected or transformed cells. But assessing their killing potential requires precision. In our latest blog, Senior Biotechnology Professional Darcey L. Clark breaks down the evolution of the Natural Killer Cell Cytotoxicity Assay and how flow cytometry transformed it. • From Radioactivity to Fluorescence — Early chromium release assays set the standard, but came with drawbacks. Flow cytometry offered a safer, faster, and more standardized alternative. • Multi-Parametric Power — Modern flow-based NK assays don’t just measure cytotoxicity—they also allow for detailed phenotyping, cytokine analysis, and functional profiling. • Human + NHP Applications — TD2’s assay supports both human and non-human primate samples and is already in use in collaboration with the CDC for disease studies. Explore how TD2 applies these advanced cytometry tools to support immune function analysis in clinical and preclinical settings: https://hubs.li/Q03f_l750 #FlowCytometry #ImmunoOncology #PreclinicalResearch

Scientific Spotlight: Identifying Treatment Pathways for Cancer Patients Explore how advanced analyses are shaping cancer treatment. In this podcast, TD2 CEO Dr. Stephen Gately and Panome Bio’s Dr. Ed Weinstein discuss the role of metabolic and proteomic techniques in guiding targeted therapies. • Focused Research: Dr. Gately and Dr. Weinstein delve into metabolic and proteomic analyses to inform cancer treatment pathways • Integrated Analyses: Combining metabolic techniques with next-generation sequencing for a comprehensive approach • Clinical Insight: Examining how obesity influences cancer development and treatment response Listen now on the TD2 website to learn more: https://hubs.li/Q03fLpF40 #Metabolomics #OncologyResearch #Podcast

Only 1 Week Away! Reserve your seat today: https://hubs.li/Q03fFWjX0 Join us in Boston/Cambridge for our upcoming Lunch & Learn: Metabolism Meets Immunotherapy: Lessons from Obese Preclinical Models 🗓️ Don’t miss this opportunity to hear expert insights from Erin Trachet and Tiffany Bernardo, PhD, BCMAS -Lunch is on us!

Too soon to talk ASCO? The countdown to #ASCO25 is on, and we will be there, armed with oncology expertise, a collaborative mindset, and a passion for helping innovators push boundaries. Don't wait for the rush—schedule a meeting today! 🔗https://hubs.li/Q03fgnz-0

🌒🐭 BREAKING: TD2 Launches Eclipse-Ready Mouse Models! We're thrilled to announce our latest scientific breakthrough: LunarMouse™, the first preclinical model specifically engineered to study totality-induced tumor regression. Early data suggest that cosmic rays, dramatic lighting, and awkward viewing angles may significantly impact tumor microenvironments. Happy April Fools’ from all of us at TD2. Sometimes you have to shoot for the moon... and land in a mouse model. #AprilFools #PreclinicalResearch #EclipseScience #MouseModels #TD2

Curious about the trends shaping ADC's and their exciting future in cancer treatment? Check out our latest blog! 🔗https://hubs.li/Q03f4byg0 #ADC #ClinicalTrials #CancerResearch #DrugDevelopment #AntibodyDrugConjugate #Oncology

Flow Cytometry Friday: Tracing a Legacy of Innovation From the early days of measuring just 1–2 cellular parameters to today’s high-throughput systems that capture 20+ fluorescent signals simultaneously, flow cytometry has come a long way. Senior Biotechnology Professional Darcey L. Clark highlights how decades of breakthroughs—from Paul Erlich’s pioneering observations to the first commercial FACS systems—have revolutionized cell analysis. • Decades of Innovation — Early instruments laid the groundwork for modern cytometers that measure thousands of particles every second. • Pioneering Milestones — Key advancements by scientists like Moldavan, Coons, Coulter, and Herzenberg transformed our understanding of cell physiology. • High-Throughput Revolution — Today’s state-of-the-art systems enable detailed immunophenotyping and rapid, multi-parametric analysis, supporting complex research and clinical applications. Discover how TD2’s expert team leverages these innovations daily with high-capacity flow cytometry services to propel research and clinical diagnostics: https://hubs.li/Q03dXf520 #FlowCytometry #Immunophenotyping #TD2

Scientific Spotlight: Advancing Cancer Immunotherapy with Predictive Biomarkers Discover how recent research is shaping immunotherapy. Our latest insights reveal that biomarkers can predict response to PD-1/PD-L1 antibody treatment, paving the way for more precise cancer care. • Focused Research: TD2 Chief Medical Officer Dr. Alan Miller and oncology experts validate an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit • Data-Driven Approach: Outcomes and genomic data guide the development of a novel Immune Response Score (IRS) • Clinical Impact: Early findings show predictive responses in select patients, with potential to extend treatment benefits to new indications Download now to learn more about advancing cancer immunotherapy: https://hubs.li/Q03dyq0Y0

TD2 is heading to the Society for Clinical Research Sites (SCRS) Oncology Site Solutions Summit, April 9–10! Our site experts, April Coburn and Joshua Townsend, are excited to connect with research professionals, share insights, and explore opportunities to collaborate on upcoming oncology trials while in Atlanta. We’re also looking forward to introducing our exclusive new Peak Partners program—an initiative designed to build strategic partnerships with high-performing research sites. If you're aiming to expand trial access, streamline operations, and work with a CRO that truly values site input, schedule a meeting today! Let’s reach new heights, together.